Radiotherapy & Oncology
Volume 96, Issue 1 , Pages 55-60 , July 2010

Clinical introduction of Monte Carlo treatment planning: A different prescription dose for non-small cell lung cancer according to tumor location and size

  • Noëlle C. van der Voort van Zyp

      Affiliations

    • Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Groene Hilledijk 301 3075 EA Rotterdam, The Netherlands.
    • ,
  • Mischa S. Hoogeman

      Affiliations

    • Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • ,
  • Steven van de Water

      Affiliations

    • Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • ,
  • Peter C. Levendag

      Affiliations

    • Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • ,
  • Bronno van der Holt

      Affiliations

    • Department of Trials & Statistics, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • ,
  • Ben J.M. Heijmen

      Affiliations

    • Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • ,
  • Joost J. Nuyttens

      Affiliations

    • Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Received 14 December 2009 ,Revised 12 March 2010 ,Accepted 5 April 2010.

References 

  1. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623–1631
  2. van der Voort van Zyp NC, Prevost JB, Hoogeman MS, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome. Radiother Oncol. 2009;91:296–300
  3. Lax I, Panettieri V, Wennberg B, et al. Dose distributions in SBRT of lung tumors: comparison between two different treatment planning algorithms and Monte-Carlo simulation including breathing motions. Acta Oncol. 2006;45:978–988
  4. Rassiah-Szegedi P, Salter BJ, Fuller CD, Blough M, Papanikolaou N, Fuss M. Monte Carlo characterization of target doses in stereotactic body radiation therapy (SBRT). Acta Oncol. 2006;45:989–994
  5. Schuring D, Hurkmans CW. Developing, evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose. Radiat Oncol. 2008;3:21
  6. Aarup LR, Nahum AE, Zacharatou C, et al. The effect of different lung densities on the accuracy of various radiotherapy dose calculation methods: implications for tumour coverage. Radiother Oncol. 2009;91:405–414
  7. Available from: http://www.aapm.org/pubs/reports/rpt_85.pdf. Tissue inhomogeneity corrections for megavoltage photon beams. AAPM 2004.
  8. Ding GX, Duggan DM, Lu B, et al. Impact of inhomogeneity corrections on dose coverage in the treatment of lung cancer using stereotactic body radiation therapy. Med Phys. 2007;34:2985–2994
  9. Vanderstraeten B, Reynaert N, Paelinck L, et al. Accuracy of patient dose calculation for lung IMRT: a comparison of Monte Carlo, convolution/superposition, and pencil beam computations. Med Phys. 2006;33:3149–3158
  10. Knoos T, Wieslander E, Cozzi L, et al. Comparison of dose calculation algorithms for treatment planning in external photon beam therapy for clinical situations. Phys Med Biol. 2006;51:5785–5807
  11. Nuyttens JJ, Prevost JB, Praag J, et al. Lung tumor tracking during stereotactic radiotherapy treatment with the CyberKnife: marker placement and early results. Acta Oncol. 2006;45:961–965
  12. Timmerman RD. A phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the treatment of patients with medically inoperable stage I/II non-small cell lung cancer. RTOG 0236.
  13. van der Voort van Zyp NC, van der Holt B, van Klaveren RJ, Pattynama P, Maat A, Nuyttens JJ. Stereotactic body radiotherapy using real-time tumor tracking in octogenarians with non-small cell lung cancer. Lung Cancer.
  14. Poll JJ, Hoogeman MS, Prevost JB, Nuyttens JJ, Levendag PC, Heijmen BJ. Reducing monitor units for robotic radiosurgery by optimized use of multiple collimators. Med Phys. 2008;35:2294–2299
  15. Hol M, Marijnissen JPA, van der Baan P, et al. Accuracy of the Monte Carlo dose calculation algorithm for Cyberknife treatment of small lung lesions [abstract]. Med Phys. 2008;35:2953
  16. Deng J, Jiang SB, Kapur A, Li J, Pawlicki T, Ma CM. Photon beam characterization and modelling for Monte Carlo treatment planning. Phys Med Biol. 2000;45:411–427
  17. Deng J, Jiang SB, Pawlicki T, Li J, Ma CM. Derivation of electron and photon energy spectra from electron beam central axis depth dose curves. Phys Med Biol. 2001;46:1429–1449
  18. Jiang SB, Kapur A, Ma CM. Electron beam modeling and commissioning for Monte Carlo treatment planning. Med Phys. 2000;27:180–191
  19. Ma C-M, Li JS, Deng J, Fan J. Implementation of Monte Carlo dose calculation for CyberKnife treatment planning. J Phys Conf Ser. 2008;102:012016
  20. Chetty IJ, Curran B, Cygler JE, et al. Report of the AAPM Task Group No. 105: issues associated with clinical implementation of Monte Carlo-based photon and electron external beam treatment planning. Med Phys. 2007;34:4818–4853
  21. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–714
  22. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, et al. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol. 2009;4:1
  23. Xiao Y, Papiez L, Paulus R, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I–II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;73:1235–1242
  24. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45:787–795
  25. Koto M, Takai Y, Ogawa Y, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2007;85:429–434

☆ Presented at the 10th Biennal ESTRO by N. vd Voort van Zyp (abstract number 159).

PII: S0167-8140(10)00235-5

doi: 10.1016/j.radonc.2010.04.009

Radiotherapy & Oncology
Volume 96, Issue 1 , Pages 55-60 , July 2010

Article Tools

* Image Usage & Resolution